ALK and non-small cell lung carcinoma: With regard to the antitumor efficacy of alectinib for BM, intracranial tumor implantation mouse models of ALK+ NSCLC cells have demonstrated that alectinib potently induces IC tumor regression compared with crizotinib, resulting in prolonged survival [26, 27].